RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Harm reduction-focused behavioral activation for people who inject drugs
Mixed methods outcomes from a pilot open trial
Paquette, C., Vierling, A., Kane, L., Abrego, P. L., Benson, K., Jordan, E., Baucom, D., Zule, W., & Daughters, S. (2024). Harm reduction-focused behavioral activation for people who inject drugs: Mixed methods outcomes from a pilot open trial. Journal of Substance Use & Addiction Treatment, 167, Article 209490. https://doi.org/10.1016/j.josat.2024.209490
Introduction: People who inject drugs (PWID) experience high rates of mental health problems and drug-related harms. Harm reduction-focused interventions aim to reduce harms associated with drug use and are an important approach for engaging people who are not seeking traditional abstinence-focused treatment. Yet, few studies to date have examined the effectiveness of harm reduction psychosocial treatment for drug use. We evaluated the outcomes of a harm reduction-focused behavioral activation (BA) intervention from pretreatment to a 1-month follow-up. Methods: A total of N = 23 PWID (65.2 % White; 52.2 % women; mean age 35.4 +/- 7.8 years) were recruited from syringe services programs and n = 19 received the intervention via teletherapy. Assessment of study outcome measures occurred at pre- and posttreatment and a one-month follow-up. Results: Results reflected post-intervention increases in behavioral activation and readiness to change drug use, as well as decreases in substance use, depression, and HIV risk behaviors. There were mixed outcomes on substancerelated problems with increases at follow-up, possibly reflecting increased problem recognition. Conclusions: These results suggest initial promise for the harm reduction-focused treatment. Additional research with randomized designs and larger sample sizes is needed, and more intensive treatment may be required to support sustained treatment gains in this population.